HIV-1-Tat excites cardiac parasympathetic neurons of nucleus ambiguus and triggers prolonged bradycardia in conscious rats

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 306, Issue 11, 2014, Pages

  Brailoiu, Eugen ^a   Deliu, Elena ^a   Sporici, Romeo A ^b   Benamar, Khalid ^a   Brailoiu, G Cristina ^c  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Autonomic cardiovascular regulation; Endoplasmic reticulum; Nucleus ambiguus; Transient receptor potential vanilloid type 2

Indexed keywords

CALCIUM; CATION CHANNEL; INOSITOL 1,4,5 TRISPHOSPHATE; RHODAMINE; TRANSACTIVATOR PROTEIN; VANILLOID RECEPTOR 2;

ADULT; AMBIGUUS NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTONOMIC DYSFUNCTION; BLOOD PRESSURE MEASUREMENT; BRADYCARDIA; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; DEPOLARIZATION; ENDOPLASMIC RETICULUM; HEART RATE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MALE; MEMBRANE DEPOLARIZATION; MICROINJECTION; MOLECULAR MECHANICS; NERVE CELL MEMBRANE; NEWBORN; NONHUMAN; PARASYMPATHETIC NERVE CELL; PREGANGLIONIC NERVE CELL; PRIORITY JOURNAL; QT PROLONGATION; RAT; SUDDEN CARDIAC DEATH;

AUTONOMIC CARDIOVASCULAR REGULATION; CYTOSOLIC CA2+, ENDOPLASMIC RETICULUM; NUCLEUS AMBIGUUS; TRANSIENT RECEPTOR POTENTIAL VANILLOID TYPE 2;

ANIMALS; BRADYCARDIA; CALCIUM; CONSCIOUSNESS; DISEASE MODELS, ANIMAL; ENDOPLASMIC RETICULUM; FEMALE; INOSITOL 1,4,5-TRISPHOSPHATE; MALE; MEDULLA OBLONGATA; MICROINJECTIONS; PARASYMPATHETIC NERVOUS SYSTEM; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRPV CATION CHANNELS;

EID: 84902682975     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00529.2013     Document Type: Article

References (63)

1. Badou A, Bennasser Y, Moreau M, Leclerc C, Benkirane M, Bahraoui E. Tat protein of human immunodeficiency virus type 1 induces interleukin-10 in human peripheral blood monocytes: implication of protein kinase C-dependent pathway. J Virol 74: 10551-10562, 2000.
2. Bang S, Kim KY, Yoo S, Lee SH, Hwang SW. Transient receptor potential V2 expressed in sensory neurons is activated by probenecid. Neurosci Lett 425: 120-125, 2007.
3. 2+ signaling in the retinal pigment epithelium: role of angiotensin-receptor-associated-protein and TRPV2 channel. PLoS One 7: e49624, 2012.
4. Becker K, Gorlach I, Frieling T, Haussinger D. Characterization and natural course of cardiac autonomic nervous dysfunction in HIV-infected patients. AIDS 11: 751-757, 1997.
5. Benamar K, Addou S, Yondorf M, Geller EB, Eisenstein TK, Adler MW. Intrahypothalamic injection of the HIV-1 envelope glycoprotein induces fever via interaction with the chemokine system. J Pharmacol Exp Ther 332: 549-553, 2010.
6. Bowman EJ, Siebers A, Altendorf K. Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. Proc Natl Acad Sci USA 85: 7972-7976, 1988.
7. 2+ overload and neuronal death in cultured rat cortical neurons. J Neurovirol 12: 17-24, 2006.
8. Brailoiu GC, Arterburn JB, Oprea TI, Chitravanshi VC, Brailoiu E. Bradycardic effects mediated by activation of G protein-coupled estrogen receptor in rat nucleus ambiguus. Exp Physiol 98: 679-691, 2013.
9. Brailoiu GC, Benamar K, Arterburn JB, Gao E, Rabinowitz JE, Koch WJ, Brailoiu E. Aldosterone increases cardiac vagal tone via GPER activation. J Physiol 591: 4223-4235, 2013.
10. Brailoiu GC, Brailoiu E, Chang JK, Dun NJ. Excitatory effects of human immunodeficiency virus 1 Tat on cultured rat cerebral cortical neurons. Neuroscience 151: 701-710, 2008.
11. Brailoiu GC, Deliu E, Tica AA, Chitravanshi VC, Brailoiu E. Urocortin 3 elevates cytosolic calcium in nucleus ambiguus neurons. J Neurochem, 2012.
12. Brailoiu GC, Deliu E, Tica AA, Rabinowitz JE, Tilley DG, Benamar K, Koch WJ, Brailoiu E. Nesfatin-1 activates cardiac vagal neurons of nucleus ambiguus and elicits bradycardia in conscious rats. J Neurochem 126: 739-748, 2013.
13. Brauner T, Hulser DF, Strasser RJ. Comparative measurements of membrane potentials with microelectrodes and voltage-sensitive dyes. Biochim Biophys Acta 771: 208-216, 1984.
14. Charbit B, Rosier A, Bollens D, Boccara F, Boelle PY, Koubaa A, Girard PM, Funck-Brentano C. Relationship between HIV protease inhibitors and QTc interval duration in HIV-infected patients: a crosssectional study. Br J Clin Pharmacol 67: 76-82, 2009.
15. Chen X, Hui L, Geiger NH, Haughey NJ, Geiger JD. Endolysosome involvement in HIV-1 transactivator protein-induced neuronal amyloid beta production. Neurobiol Aging 34: 2370-2378, 2013.
16. Cheng J, Nath A, Knudsen B, Hochman S, Geiger JD, Ma M, Magnuson DS. Neuronal excitatory properties of human immunodeficiency virus type 1 Tat protein. Neuroscience 82: 97-106, 1998.
17. Chitravanshi VC, Kawabe K, Sapru HN. Bradycardic effects of microinjections of urocortin 3 into the nucleus ambiguus of the rat. Am J Physiol Regul Integr Comp Physiol 303: R1023-R1030, 2012.
18. Chow DC, Wood R, Choi J, Grandinetti A, Gerschenson M, Sriratanaviriyakul N, Nakamoto B, Shikuma C, Low P. Cardiovagal autonomic function in HIV-infected patients with unsuppressed HIV viremia. HIV Clin Trials 12: 141-150, 2011.
19. Clark JP, 3rd Sampair CS, Kofuji P, Nath A, Ding JM. HIV protein, transactivator of transcription, alters circadian rhythms through the light entrainment pathway. Am J Physiol Regul Integr Comp Physiol 289: R656-R662, 2005.
20. Debaisieux S, Rayne F, Yezid H, Beaumelle B. The ins and outs of HIV-1 Tat. Traffic 13: 355-363, 2012.
21. Eletto D, Russo G, Passiatore G, Del Valle L, Giordano A, Khalili K, Gualco E, Peruzzi F. Inhibition of SNAP25 expression by HIV-1 Tat involves the activity of mir-128a. J Cell Physiol 216: 764-770, 2008.
22. Fang Q, Kan H, Lewis W, Chen F, Sharma P, Finkel MS. Dilated cardiomyopathy in transgenic mice expressing HIV Tat. Cardiovasc Toxicol 9: 39-45, 2009.
23. Feligioni M, Raiteri L, Pattarini R, Grilli M, Bruzzone S, Cavazzani P, Raiteri M, Pittaluga A. The human immunodeficiency virus-1 protein Tat and its discrete fragments evoke selective release of acetylcholine from human and rat cerebrocortical terminals through species-specific mechanisms. J Neurosci 23: 6810-6818, 2003.
24. Fiorentini A, Petrosillo N, Di Stefano A, Cicalini S, Borgognoni L, Boumis E, Tubani L, Chinello P. QTc interval prolongation in HIVinfected patients: a case-control study by 24-hour Holter ECG recording. BMC Cardiovasc Disord 12: 124, 2012.
25. Fisher SD, Kanda BS, Miller TL, Lipshultz SE. Cardiovascular disease and therapeutic drug-related cardiovascular consequences in HIV-infected patients. Am J Cardiovasc Drugs 11: 383-394, 2011.
26. Freeman R, Roberts MS, Friedman LS, Broadbridge C. Autonomic function and human immunodeficiency virus infection. Neurology 40: 575-580, 1990.
27. Giacca M. The HIV-1 Tat protein: a multifaceted target for novel therapeutic opportunities. Curr Drug Targets Immune Endocr Metabol Disord 4: 277-285, 2004.
28. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 260: 3440-3450, 1985.
29. Haughey NJ, Holden CP, Nath A, Geiger JD. Involvement of inositol 1,4,5-trisphosphate-regulated stores of intracellular calcium in calcium dysregulation and neuron cell death caused by HIV-1 protein tat. J Neurochem 73: 1363-1374, 1999.
30. Hui L, Chen X, Haughey NJ, Geiger JD. Role of endolysosomes in HIV-1 Tat-induced neurotoxicity. ASN Neuro 4: 243-252, 2012.
31. Irnaten M, Aicher SA, Wang J, Venkatesan P, Evans C, Baxi S, Mendelowitz D. Mu-opioid receptors are located postsynaptically and endomorphin-1 inhibits voltage-gated calcium currents in premotor cardiac parasympathetic neurons in the rat nucleus ambiguus. Neuroscience 116: 573-582, 2003.
32. Johnson TP, Patel K, Johnson KR, Maric D, Calabresi PA, Hasbun R, Nath A. Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein. Proc Natl Acad Sci USA 110: 13588-13593, 2013.
33. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, Boccara F, Costagliola D. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 170: 1228-1238, 2010.
34. Lewinter RD, Scherrer G, Basbaum AI. Dense transient receptor potential cation channel, vanilloid family, type 2 (TRPV2) immunoreactivity defines a subset of motoneurons in the dorsal lateral nucleus of the spinal cord, the nucleus ambiguus and the trigeminal motor nucleus in rat. Neuroscience 151: 164-173, 2008.
35. Li W, Li G, Steiner J, Nath A. Role of Tat protein in HIV neuropathogenesis. Neurotox Res 16: 205-220, 2009.
36. Lu SM, Tremblay ME, King IL, Qi J, Reynolds HM, Marker DF, Varrone JJ, Majewska AK, Dewhurst S, Gelbard HA. HIV-1 Tatinduced microgliosis and synaptic damage via interactions between peripheral and central myeloid cells. PLoS One 6: e23915, 2011.
37. Mayne M, Holden CP, Nath A, Geiger JD. Release of calcium from inositol 1,4,5-trisphosphate receptor-regulated stores by HIV-1 Tat regulates TNF-α production in human macrophages. J Immunol 164: 6538-6542, 2000.
38. Mendelowitz D. Brainstem premotor cardiac vagal neurons. In: Neural Mechanisms of Cardiovascular Regulation, edited by Dun NJ, Machado BH, and Paul M, New York: Kluwer Academic Publishers, p. 371-397, 2004.
39. 2+-dependent desensitization of TRPV2 channels is mediated by hydrolysis of phosphatidylinositol 4,5-bisphosphate. J Neurosci 30: 13338-13347, 2010.
40. Mittal CM, Wig N, Mishra S, Deepak KK. Heart rate variability in human immunodeficiency virus-positive individuals. Int J Cardiol 94: 1-6, 2004.
41. Mocchetti I, Bachis A, Avdoshina V. Neurotoxicity of human immunodeficiency virus-1: viral proteins and axonal transport. Neurotox Res 21: 79-89, 2012.
42. Monet M, Gkika D, Lehen'kyi V, Pourtier A, Vanden Abeele F, Bidaux G, Juvin V, Rassendren F, Humez S, Prevarsakaya N. Lysophospholipids stimulate prostate cancer cell migration via TRPV2 channel activation. Biochim Biophys Acta 1793: 528-539, 2009.
43. Nath A, Geiger J. Neurobiological aspects of human immunodeficiency virus infection: neurotoxic mechanisms. Prog Neurobiol 54: 19-33, 1998.
44. Nie L, Kanzaki M, Shibata H, Kojima I. Activation of calciumpermeable cation channel by insulin in Chinese hamster ovary cells expressing human insulin receptors. Endocrinology 139: 179-188, 1998.
45. 2+-permeable channel. Cell Calcium 22: 75-82, 1997.
46. Pocernich CB, Sultana R, Mohmmad-Abdul H, Nath A, Butterfield DA. HIV-dementia, Tat-induced oxidative stress, and antioxidant therapeutic considerations. Brain Res Brain Res Rev 50: 14-26, 2005.
47. Reinsch N, Buhr C, Krings P, Kaelsch H, Neuhaus K, Wieneke H, Erbel R, Neumann T. Prevalence and risk factors of prolonged QTc interval in HIV-infected patients: results of the HIV-HEART study. HIV Clin Trials 10: 261-268, 2009.
48. Robinson-Papp J, Sharma S, Simpson DM, Morgello S. Autonomic dysfunction is common in HIV and associated with distal symmetric polyneuropathy. J Neurovirol 19: 172-180, 2013.
49. Romani B, Engelbrecht S, Glashoff RH. Functions of Tat: the versatile protein of human immunodeficiency virus type 1. J Gen Virol 91: 1-12, 2010.
50. Rumbaugh JA, Steiner J, Sacktor N, Nath A. Developing neuroprotective strategies for treatment of HIV-associated neurocognitive dysfunction. Fut HIV Ther 2: 271-280, 2008.
51. Sani MU, Okeahialam BN. QTc interval prolongation in patients with HIV and AIDS. J Natl Med Assoc 97: 1657-1661, 2005.
52. Schoniger S, Wehming S, Gonzalez C, Schobitz K, Rodriguez E, Oksche A, Yulis CR, Nurnberger F. The dispersed cell culture as model for functional studies of the subcommissural organ: preparation and characterization of the culture system. J Neurosci Methods 107: 47-61, 2001.
53. Squires KE, Young B, DeJesus E, Bellos N, Murphy D, Sutherland-Phillips DH, Zhao HH, Patel LG, Ross LL, Wannamaker PG, Shaefer MS. Safety and efficacy of a 36-week induction regimen of abacavir/ lamivudine and ritonavir-boosted atazanavir in HIV-infected patients. HIV Clin Trials 11: 69-79, 2010.
54. Squires KE, Young B, DeJesus E, Bellos N, Murphy D, Ward D, Zhao HH, Ross LL, Shaefer MS. ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/ abacavir/lamivudine. HIV Clin Trials 13: 233-244, 2012.
55. Squires KE, Young B, Dejesus E, Bellos N, Murphy D, Zhao HH, Patel LG, Ross LL, Wannamaker PG, Shaefer MS. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. AIDS 24: 2019-2027, 2010.
56. Sui Z, Fan S, Sniderhan L, Reisinger E, Litzburg A, Schifitto G, Gelbard HA, Dewhurst S, Maggirwar SB. Inhibition of mixed lineage kinase 3 prevents HIV-1 Tat-mediated neurotoxicity and monocyte activation. J Immunol 177: 702-711, 2006.
57. Trinkley KE, Lee Page R, 2nd Lien H, Yamanouye K, Tisdale JE. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Curr Med Res Opin 29: 1719-1726, 2013.
58. Tseng ZH, Secemsky EA, Dowdy D, Vittinghoff E, Moyers B, Wong JK, Havlir DV, Hsue PY. Sudden cardiac death in patients with human immunodeficiency virus infection. J Am Coll Cardiol 59: 1891-1896, 2012.
59. Villa A, Foresti V, Confalonieri F. Autonomic neuropathy and prolongation of QT interval in human immunodeficiency virus infection. Clin Auton Res 5: 48-52, 1995.
60. Wayman WN, Dodiya HB, Persons AL, Kashanchi F, Kordower JH, Hu XT, Napier TC. Enduring cortical alterations after a single in-vivo treatment of HIV-1 Tat. Neuroreport 23: 825-829, 2012.
61. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, Monforte AD, Friis-Moller N, Kirk O, Fontas E, Weller I, Phillips A, Lundgren J. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 201: 318-330, 2010.
62. Young B, Squires KE, Ross LL, Santiago L, Sloan LM, Zhao HH, Wine BC, Pakes GE, Margolis DA, Shaefer MS. Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES. AIDS Res Hum Retroviruses 29: 350-358, 2013.
63. Zhao H, Goetz MB. Complications of HIV infection in an ageing population: challenges in managing older patients on long-term combination antiretroviral therapy. J Antimicrob Chemother 66: 1210-1214, 2011.